PRSS22

Across TCGA pan-cancer cohorts, PRSS22 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRSS22 data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PRSS22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRSS22 expression acts as an unfavorable survival marker.

LUSC and STAD are the cancer types where PRSS22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.156	0.675	.014	24	view →
STAD	OS	Median	All	0.250	0.729	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PRSS22–LUSC (OS)

Open the LUSC breakdown →